Hyperbaric Oxygen Treatment Induces a 2-Phase Antinociceptive Response of Unusually Long Duration in Mice

Eunhee Chung,* Lisa M. Zelinski,* Yusuke Ohgami,* Donald Y. Shirachi,‡ and Raymond M. Quock*,†

*Department of Pharmaceutical Sciences, College of Pharmacy.
†Center for Integrated Biotechnology, Washington State University, Pullman, Washington.
‡Chico Hyperbaric Center, Chico, California.

Abstract: Hyperbaric oxygen (HBO_2) therapy is approved by the FDA for limited clinical indications but is reported to produce pain relief in several chronic pain conditions. However, there have been no studies to explain this apparent analgesic effect of HBO_2. Research conducted in our laboratory demonstrates that 4 daily 60-minute HBO_2 treatments at 3.5 absolute atmospheres induced an unparalleled antinociceptive response that consists of 1) an early phase that lasted at least 6 hours after the HBO_2 treatment before dissipating; and 2) a late phase that emerged about 18 hours after the early phase and lasted for up to 3 weeks. The early phase was sensitive to antagonism by acutely intracerebroventricular (i.c.v.)-administered opioid antagonist naltrexone and the nitric oxide synthase (NOS)-inhibitor L-NAME. The late phase was inhibited by treatment with i.c.v. naltrexone or L-NAME during the 4 daily HBO_2 treatments but was not antagonized by either naltrexone or L-NAME following acute pretreatment 2 weeks after HBO_2 treatment. These experimental results implicate a novel mechanism that is activated by HBO_2, resulting in an antinociceptive response of unusually long duration that is of potential interest in the clinical management of pain.

Perspective: Hyperbaric oxygen treatment of mice can induce a 2-phase antinociceptive response of unusually long duration. Nitric oxide and opioid receptors appear to initiate or mediate both phases of the antinociceptive response. Further elucidation of the underlying mechanism may potentially identify molecular targets that cause long-lasting activation of endogenous analgesic systems.

© 2010 by the American Pain Society
Key words: Hyperbaric oxygen, antinociception, nitric oxide, opioid receptors, mice.

Hyperbaric oxygen (HBO_2) therapy is the clinical application of 100% oxygen at higher than atmospheric pressures for limited periods of time (60–90 minutes) to achieve therapeutic outcomes. HBO_2 treatment is approved by the U.S. Food and Drug Administration (FDA) for only a limited number of conditions, which include primarily decompression sickness (the "bends"), carbon monoxide poisoning, cerebral arterial gas embolus, osteoradionecrosis, and clostridial myonecrosis (gas gangrene).[9]

However, there are reports that HBO_2 treatment can also be effective in a number of nonapproved condi-

tions. Among these conditions that are reportedly responsive to HBO_2 therapy are a variety of chronic pains, for which intermittent exposure to HBO_2 reportedly causes a long-lasting analgesic effect. Patients suffering from complex regional pain syndrome (CRPS or reflex sympathetic dystrophy syndrome) experienced less pain following HBO_2 therapy.[14,21,25] Significant pain reduction was also reported in patients with generalized allodynia/hyperalgesia as a consequence of fibromyalgia syndrome (FMS).[32] Patients suffering from migraine headache or cluster headache also reported pain relief following HBO_2 therapy.[6,17,31] Pain associated with radiotherapy of cancer has also been reported to be alleviated by HBO_2 therapy.[4,13,18]

Animal studies related to HBO_2 treatment of pain have been limited, and prior studies have focused largely on the peripheral antiinflammatory effect rather than a central antinociceptive effect of HBO_2.[22,28] More recently, inflammatory pain induced by carrageenan in rats was evaluated after HBO_2 exposure at 2.4 absolute atmospheres (ATA) for 90 minutes.[29] HBO_2 treatment was found to reduce inflammation (as determined by

reduced paw swelling) as well as mechanical hypersensitivity (as determined by increased threshold for paw withdrawal).[30] The ability of HBO₂ treatment to reduce inflammation and pain was comparable to that of acetylsalicylic acid treatment.[29] It is notable that there was a temporal dissociation of the antiinflammatory and antinociceptive effects. The anti-inflammatory effect was almost immediate after carrageenan was administered to HBO₂-treated rats, while the antinociceptive effect did not manifest itself until nearly 2 hours after the HBO₂ treatment.

We recently reported that a 60-minute exposure to 100% oxygen (O_2) at 3.5 absolute atmospheres produced an antinociceptive effect of at least 90 minutes' duration that involves opioid and nitric oxide (NO) mechanisms.[33] Mice exposed to HBO₂ for 60 minutes were returned to room air, after which antinociception was assessed. The antinociceptive effect was significantly attenuated by intracerebroventricular (i.c.v.) pretreatment with 2 inhibitors of nitric oxide synthase (NOS) enzyme, the nonselective inhibitor N^G-nitro-L-arginine methyl ester (L-NAME), and the neuronally-selective inhibitor S-methyl-L-thiocitrulline (SMTC). The endothelial-selective NOS-inhibitor N^5-(1-iminoethyl)-L-ornithine (L-NIO) administered ip just prior to the start of HBO₂ treatment had no effect on the antinociceptive response. The antinociceptive effect at 90 minutes was also markedly antagonized by ip pretreatment with the opioid receptor blocker naltrexone. Confirming an involvement of endogenous opioid peptides in the antinociception, the effect was found to be sensitive to antagonism by i.c.v. pretreatment with a rabbit antiserum against rat dynorphin but not by antisera against either β-endorphin or methionine-enkephalin. The prolonged antinociceptive effect at 90 minutes after HBO₂-induced treatment was also significantly attenuated by naltrexone—but not L-NAME—administered 75 minutes following HBO₂ treatment but 15 minutes prior to nociceptive testing. Based on these experimental findings, we concluded that the HBO₂-induced antinociceptive effect involves both NO and opioid mechanisms in the brain and is consistent with our hypothesis that HBO₂ can stimulate an NO-dependent neuronal release of dynorphin, which, in turn, activates κ opioid receptors that mediate antinociception.

The present study grew out of an attempt to determine whether repeated sessions of HBO₂ treatment might prolong the duration of the HBO₂-induced antinociception and to pharmacologically characterize the antinociceptive response.

Methods

Animals

Male NIH Swiss mice, weighing 18 to 22 g, were purchased from Harlan Laboratories (Indianapolis, IN) and used in this study, which was approved by an institutional animal care and use committee with post-approval review and carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23, revised 1996). All measures to minimize pain or discomfort were taken by the investigators.

Mice were housed in the AAALAC-accredited Wegner Hall Vivarium with access to food and water ad libitum. The facility was maintained on a 12-hour light/dark cycle (lights on 0700 to 1900 hours) under standard conditions ($22 \pm 1°C$ room temperature, 33% humidity). Mice were kept in the holding room for at least 4 days after arrival in the facility for acclimation prior to experimentation.

Exposure to Hyperbaric Oxygen (HBO₂)

Cages of 5 mice each were placed in a B-11 research hyperbaric chamber (Reimers Systems, Inc.; Lorton, VA) as previously described.[20] The chamber was ventilated with 100% oxygen (O_2), U.S.P. (A-L Compressed Gases, Inc, Spokane, WA) at a flow rate of 20 L/minute to minimize carbon dioxide accumulation. The pressure within the cylindrical clear acrylic chamber (27.9 cm diameter × 55.9 cm L) was increased at a rate of 1.0 ATA/min to the desired pressure (3.5 ATA) and maintained for 60 minutes. The mice were allowed to breathe spontaneously during HBO₂ treatment. After completion of the HBO₂ exposure, mice were then decompressed at a rate of 1.0 ATA/min. Control groups of mice were exposed to compressed air (A-L Compressed Gases) circulated through the chamber at 1.0 ATA and maintained for 60 minutes. Decompression typically took 4-5 min.

Mice were subjected to HBO₂ treatment at 3.5 ATA for 60 minutes between 1000 and 1100 hours for 4 consecutive days. At different time intervals following the fourth HBO₂ session, different groups of mice were assessed for antinociceptive responsiveness, as described in the following section, due to loss of sensitivity to acetic acid for several days following injection.

Antinociceptive Testing

Antinociceptive responsiveness was assessed using the abdominal constriction test as previously described.[8] At varying time intervals following HBO₂ treatment, different groups of mice were treated ip with .1 mL per 10 g body weight of .6% glacial acetic acid and placed into an open clear Plexiglas chamber (35 cm L × 20 cm W × 15 cm H). Exactly 5 minutes later, the number of abdominal constrictions—lengthwise stretches of the torso with concave arching of the back—in each animal was counted for six-minute periods for each treatment group. Multiple raters were used for some but not all experiments; at least 1 of the raters was blinded to the drug treatment. The control reference group was exposed to room air. The degree of antinociception (inhibition of abdominal constrictions) produced in various treatment groups of mice was calculated as:

$$\% \text{ antinociception} = 100 \times \frac{\#\text{constrictions in control mice} - \#\text{constrictions in pretreated mice}}{\#\text{constrictions in control mice}}$$

A mean number of abdominal constrictions was determined for control mice and was used as the basis for

determining the percent antinociceptive response for each experimental mouse at a specific time point or in a particular pretreatment group. In the time-course experiment, different groups of at least 6 mice were tested at each time interval following HBO$_2$ treatment because the ip injection desensitizes for up to 5 days the sensory receptors that initiate the abdominal constrictions.

Drugs

The following drugs were used in this research: naltrexone hydrochloride (Tocris Bioscience, Ellisville, MO); and L-N^G-nitro arginine methyl ester (L-NAME) (Research Biochemicals International, Natick, MA). Naltrexone and L-NAME were freshly prepared daily in sterile .9% physiological saline solution and administered acutely or chronically into the lateral cerebral ventricle. Control animals received vehicle (physiological saline solution) via the same route.

Acute Intracerebroventricular Microinjection Procedure

Acute i.c.v. microinjections of 1.0 μg naltrexone or L-NAME were made using the microinjection technique of Haley and McCormick.[10] Briefly, mice were anesthetized with isoflurane, U.S.P. (Abbott Laboratories, N. Chicago, IL). A short incision was made along the midline of the scalp using a scalpel, and the skin was pulled back to expose the calvarium. The i.c.v. microinjection was made using a 10-μL microsyringe (Hamilton, Reno, NV) with a 26-gauge cemented needle. The microsyringe was held vertically by hand at a point on the calvarium 2.0 mm lateral and 1.0 mm caudal from bregma to a depth of −2.0 mm from the skull surface. Penetration was controlled by a large-bore needle through which the microsyringe needle was inserted; the hypodermic needle which served as a collar to limit penetration of the microsyringe needle to 2.0 mm. A volume of 4.0 μL of drug solution was delivered directly into the lateral cerebral ventricle over 30 seconds.

Chronic Intracerebroventricular Infusion Procedure

For chronic i.c.v. delivery of 1.0 μg/day naltrexone and L-NAME during the 4-day HBO$_2$ treatment, mice were anaesthetized with isoflurane and brain infusion cannulae (Alza, Cupertino, CA) were implanted into the lateral cerebral ventricle. Each brain infusion cannula was connected to a dorsally, subcutaneously implanted Alzet osmotic minipump model 2001 (200-μL reservoir, 1.0 ± .04 μL/hr pumping rate, delivers for up to 1 week) with polyvinylchloride tubing. The concentration of naltrexone and L-NAME stored in each minipump was .0416 μg/μL. The osmotic minipumps were implanted prior to the first HBO$_2$ treatment and were removed immediately following the fourth HBO$_2$ treatment.

Statistical Analysis of Data

Percent changes in antinociception were arc-sine-transformed to normalize the distribution of percentages prior to statistical analysis. A 1-way ANOVA and post hoc Bonferroni's multiple comparison test was used to compare HBO$_2$-induced antinociception in various pretreatment groups.

Results

Time Course of HBO$_2$ -Induced Antinociception

Fig 1 shows the time course of the biphasic antinociceptive response following 4 daily HBO$_2$ treatments at 3.5 ATA of 60 minutes each. HBO$_2$ treatment produced a robust antinociceptive response (approximately 90 to 95% suppression of abdominal constrictions) that lasted for up to 6 hours following the last HBO$_2$ session.

When antinociceptive testing was conducted after additional time intervals, it was discovered that the antinociceptive effect of HBO$_2$ had completely dissipated by


Figure 1. Time course of antinociceptive response to 4 daily 60-minute HBO$_2$ treatment: **(A)** an early-phase response that lasts at least 6 hours after HBO$_2$ treatment and dissipating by 12 hours; and **(B)** a late-phase antinociceptive response that emerges 24 hours (1 day) after HBO$_2$ treatment and lasts for up to 21 days (3 weeks) following HBO$_2$ treatment. The data are expressed as the mean ± S.E.M. of at least 6 mice per group.

Figure 2. Influence of acute i.c.v. pretreatment with vehicle (VEH), 1.0 μg naltrexone (NTX), and 1.0 μg L-NAME on the HBO$_2$-induced early-phase antinociceptive response 3 hours after the fourth HBO$_2$ treatment. The data are expressed as the mean $\pm$ S.E.M. of 8 to 12 mice per group. Significance of difference: ***, $P < .001$, compared to HBO$_2$ control group (1-way ANOVA and post hoc Bonferroni's multiple comparison test).

Figure 3. Influence of acute i.c.v. pretreatment with vehicle (VEH), 1.0 μg naltrexone (NTX), and 1.0 μg L-NAME on the HBO$_2$-induced late-phase antinociceptive response 14 days after the fourth HBO$_2$ treatment. The data are expressed as the mean $\pm$ S.E.M. of 8 to 12 mice per group. There were no significant differences among these 3 groups.

12 hours but began to re-emerge 24 hours after the last HBO$_2$ treatment. This delayed antinociceptive effect—now called the late-phase response to differentiate it from the 6-hour-long early-phase effect—proved to be equal in antinociceptive intensity to the earlier response and persisted for 14 days after the last HBO$_2$ session. At 21 days after the last session, the antinociceptive response was still at 40%.

Influence of Acute Naltrexone and L-NAME Pretreatment on the HBO$_2$-Induced Early-Phase Antinociceptive Response

Fig 2 shows the influence of naltrexone and L-NAME pretreatments 3 hours after the last HBO$_2$ treatment and 30 minutes prior to the glacial acetic acid challenge. I.c.v. pretreatment with 1.0 μg naltrexone caused a 50% reduction in the magnitude of the HBO$_2$-induced antinociceptive effect. Similar i.c.v. pretreatment with 1.0 μg L-NAME reduced the HBO$_2$-induced response by 40%.

Influence of Acute Naltrexone and L-NAME Pretreatment on the HBO$_2$-Induced Late-Phase Antinociceptive Response

We then assessed the influence of naltrexone and L-NAME on the late-phase antinociceptive response following the 4-day HBO$_2$ treatment. Fig 3 shows the influence of i.c.v.-administered naltrexone (1.0 μg) and L-NAME (1.0 μg) 14 days after the last HBO$_2$ treatment

and 30 minutes prior to the glacial acetic acid challenge. Neither pretreatment had any effect on the magnitude of the HBO$_2$-induced late-phase antinociceptive effect.

Influence of Continuous Naltrexone and L-NAME Pretreatment on the HBO$_2$-Induced Late-Phase Antinociceptive Response

Finally, we wanted to determine whether opioid receptor blockade or inhibition of NO production during HBO$_2$ exposure had any effect on development of the late-phase antinociception. Naltrexone (1.0 μg/day) and L-NAME (1.0 μg/day) were continuously delivered into the lateral cerebral ventricle using osmotic minipumps during the 4-day period in which mice were exposed to HBO$_2$ for 60 minutes each day. Immediately following the fourth day of HBO$_2$ treatment, the osmotic minipumps were removed and mice were returned to the vivarium. Two weeks later, the mice were tested for nociceptive responsiveness to the glacial acetic acid. Fig 4 shows that both naltrexone and L-NAME treatments during HBO$_2$ exposure significantly reduced the intensity of the HBO$_2$-induced late-phase antinociceptive response.

Discussion

HBO$_2$ and Nitric Oxide Function

During HBO$_2$ therapy in humans breathing room air (21% O$_2$) at 1.0 ATA, the alveolar pO$_2$ (pAO$_2$) is

Figure 4. Influence of continuously delivered i.c.v. vehicle (VEH), 1.0 μg/day naltrexone (NTX), and 1.0 μg/day L-NAME on the HBO$_2$-induced late-phase antinociceptive response 14 days after the fourth HBO$_2$ treatment. Osmotic minipumps containing VEH, NTX, or L-NAME were activated prior to the first HBO$_2$ treatment and removed immediately after the fourth HBO$_2$ treatment. The data are expressed as the mean ± S.E.M. of 8 to 12 mice per group. Significance of difference: **, $P <$ .01 and ***, $P <$ .001, compared to HBO$_2$ control group (1-way ANOVA and post hoc Bonferroni's multiple comparison test).

approximately 102 mm Hg; breathing 100% oxygen increases the pAO$_2$ to 673 mm Hg. During HBO$_2$ therapy, the pAO$_2$ increases rapidly as the pressure in the hyperbaric chamber increases. At 2.0 ATA, the pAO$_2$ rises to 1433 mm Hg; at 2.5 ATA, it is about 1813 mm Hg, a 17-fold increase as compared to breathing air at 1.0 ATA.[12] These partial pressures are attained within minutes, depending upon the rate of compression. Thus, it is expected that the tissue O$_2$ concentration throughout the body will correspondingly increase in a relatively rapid manner.

This rapid increase has been shown in vivo in the rat brain.[24] As monitored by NO- and O$_2$-specific electrodes implanted in the cerebral cortex of ketamine/xylazine-anesthetized rats, HBO$_2$ exposures at 2.0 to 2.8 ATA rapidly increased the pO$_2$ and NO within ~2 minutes. The NO concentration increased from 36 nM at 1.0 ATA to 641 nM at 2.0 ATA and 692 nM at 2.8 ATA, the latter about a 19-fold increase. So there appears to be a clear relationship between pO$_2$ and tissue NO concentration in the brain.

An in vivo microdialysis study in rats has also shown that HBO$_2$ treatment at 3.0 ATA for 120 minutes elevated NO metabolites in the hippocampus and striatum.[7] In a more recent study,[19] a 60-minute HBO$_2$ treatment caused site-specific changes in levels of the stable NO metabolites (NO$_x$)—nitrite (NO$_2^-$) and nitrate (NO$_3^-$)—in rat

brain regions and spinal cord. Exposure to 100% O$_2$ alone generally reduced regional brain and spinal cord levels of nitrite and nitrate, while exposure to compressed air at 3.5 ATA had little effect on tissue levels of NO metabolites. However, the combination of 100% O$_2$ and pressure (ie, HBO$_2$) generally increased tissue levels of both nitrite and nitrate, which serve as an index of increased NO production in selected brain regions, most notably in the striatum, brainstem, cerebellum, and spinal cord. Thus, these data suggest that at hyperbaric pressures, molecular oxygen can be converted to NO.

There is always the potential that the effects observed in this study may be associated to O$_2$ toxicity. Rats exposed to 5 to 6 ATA HBO$_2$ have been shown to exhibit EEG seizure patterns.[1,2,5] The onset of these seizures were delayed by the nNOS inhibitor, 7-nitroindazole, suggesting the involvement of NO and/or oxygen radicals. However, exposure for 75 minutes at 4 ATA did not demonstrate any seizure patterns.[5] What these data suggest that, under our experimental condition of 3.5 ATA, our results do not appear to reflect a toxic effect of HBO$_2$.

Recent research has also shown that mice can tolerate as much as 6.0 ATA HBO$_2$ and exhibit seizures only if there is preconditioning by 60-minute twice daily HBO$_2$ treatments at 2.5 ATA for 3 consecutive days.[16] Preconditioning led to an increase in levels of protein and mRNA of eNOS and nNOS in the hippocampus and hypothalamus. Our 4 daily 60-minute HBO$_2$ treatments in the present study did not appear to sensitize the mice to oxygen-induced toxicity.

Antinociceptive Responsiveness of Rats to HBO$_2$ Treatment

All of the discussion above supports our recent report that antinociception occurs very rapidly, that is, within 5 minutes of HBO$_2$ exposure at 3.5 ATA.[20,34] If the HBO$_2$ exposure is continued for 60 minutes, the antinociception is extended beyond the duration of the HBO$_2$ exposure for at least 90 minutes and, at 150 minutes, about 40% of the antinociception still remained.[33] The exact mechanism by which this HBO$_2$-induced antinociception is prolonged is not clear at this time.

Interestingly, in the present study, administration of the 60-minute HBO$_2$ treatment for 4 consecutive days extends the duration of antinociception during the early-phase response 4-fold to 6 hours. It is interesting to note here that the duration of this antinociceptive effect (early-phase antinociception) is a multiple of the 90-minute effect observed after a single HBO$_2$ exposure. This may suggest that HBO$_2$ treatment induces some type of up-regulation mechanism, which has been reported recently by others.[3,15,23]

Even more interesting is that after 4 daily 60-minute exposures of HBO$_2$, a second antinociception period (ie, the late-phase response) is initiated 24 hours after the last HBO$_2$ exposure. The level of antinociception increased over 4 days and peaked on the fifth day after the last HBO$_2$ session. This peak level of antinociception

equaled that of the early-phase response in magnitude and was maintained for another 9 days, at which time it gradually decreased to about 45% antinociception by 3 weeks after HBO$_2$ treatment. What this suggests is that an antinociceptive pathway is clearly being up-regulated in the absence of HBO$_2$ exposure. That would suggest that there was activation and/or inhibition of particular genes in the central nervous system, meaning that changes in gene regulation had possibly occurred under HBO$_2$ treatment.

Recently it was reported that rats treated daily for 5 days with HBO$_2$ for 60 minutes at 3.5 ATA showed distinct changes in gene function in the hippocampal CA1 region as assessed by DNA microarray analysis.[11] These HBO$_2$-treated animals were subjected to forebrain ischemia. Ischemic neuronal damage in the hippocampal CA1 was determined and showed that the prior HBO$_2$ treatment decreased the amount of neuronal damage. Seven genes with their respective proteins presumed to be related to the neuroprotective effect of HBO$_2$ were found to be up-regulated. The peak gene expression occurred generally at 12 hours, and the Western blot analysis of their respective proteins peaked at 24 hours. If gene regulation is involved in the late-phase antinociceptive response in the present study, then it would appear that the half-life of the proteins involved in the antinociception observed is much longer than in the previous study.[33] This requires a closer examination of the genes and proteins that might possibly be involved in the antinociceptive response.

Characterization of the HBO$_2$-Induced Early-Phase Antinociceptive Response

The present results show that, after 4 daily 60-minute HBO$_2$ treatments, the early-phase antinociceptive effect is sensitive to antagonism by naltrexone administered i.c.v. 3 hours after the HBO$_2$ treatment. This suggests that the early-phase antinociceptive response was mediated by opioid receptors and is in agreement with our previous finding that naltrexone antagonized the antinociceptive effect demonstrated after a single 60-minute exposure to HBO$_2$.[33] It is highly unlikely that O$_2$ directly interacts with opioid receptors, which are not known to contain a heme group in their molecular structure. In addition, there is no evidence that hyperoxemia leads to direct activation of opioid receptors. The early-phase antinociception was also antagonized by L-NAME, a NOS-inhibitor. This also agrees with our data on antagonism by L-NAME of the 90-minute antinociceptive response to a single 60-minute exposure to HBO$_2$.[33] The naltrexone and L-NAME antagonisms of the early-phase antinociceptive response might imply that there might be a relationship between NO and endogenous opiate release, as previously proposed.

Characterization of the HBO$_2$-Induced Late-Phase Antinociceptive Response

Acute i.c.v. treatment with naltrexone 2 weeks after the 4-day HBO$_2$ treatment had no effect on the late-phase antinociceptive response as contrasted with its influence on the early-phase antinociception. Similarly, acute i.c.v. administration of L-NAME failed to have any influence on the late-phase antinociceptive effect. This appears to indicate that the early- and late-phase antinociceptive effects of HBO$_2$ are not immediately mediated by the same mechanisms.

By using osmotic minipump technology, L-NAME and naltrexone were continuously administered i.c.v. during the 4-day HBO$_2$ treatment to determine their influence on HBO$_2$-induced antinociception. The late-phase antinociception induced by HBO$_2$ was inhibited ~80% by naltrexone and ~70% by L-NAME. Thus, it appears that there is an action of HBO$_2$ at the time of exposure that requires NO and/or opioid receptor activation in order for the late-phase antinociceptive response to develop. But the final step in the antinociceptive pathway is downstream and is not immediately mediated by NO or opioid mechanisms.

The late-phase antinociceptive effect developed only after 4 daily 60-minute HBO$_2$ treatments and was not evident after a single 60-minute HBO$_2$ exposure. Multiple-dosing or exposures of patients or experimental animals to HBO$_2$ appear to be very complicated. In the first instance, the usual HBO$_2$ treatment is 60 to 90 minutes once a day, so the HBO$_2$ exposure is relatively short over a 24-hour time period. This would necessarily imply that some endogenous mechanism is activated or invoked to sustain the pharmacological effect of HBO$_2$ beyond a 24-hour period. Up-regulation might be at least part of the answer.

A varying multiple-dosing schedule for HBO$_2$ therapy has been reported in the treatment of patients with retinitis pigmentosa (RP).[26] In this study, the patients were exposed to HBO$_2$ at 2.2 ATA for 90 minutes. The exposure or dosing schedule was the following: daily exposure for 5 days for 4 weeks followed by 5 exposures once a month for 11 months and, finally, 5 exposures once every 3 months for 2 years. The results showed a significant increase in electroretinogram measurements as compared to controls. A 10-year study conducted by the same investigators[27] employed the same dosing schedule but increasing the duration of the final regimen (5 exposures every 3 months) from 3 years to 10 years. Results showed that different visual acuity measurements were significantly higher than for controls. In these studies, the turnover of the functional proteins involved appeared to be relatively long, ie, approximately 3 months in duration. By comparison, in the present investigation, the turnover of the key proteins involved in the late-phase antinociceptive pathway appears to be somewhat shorter, about 2 to 3 weeks.

It remains to be determined whether increasing the number of HBO$_2$ exposures or that periodic re-exposure to HBO$_2$ will further extend the duration of the late-phase antinociceptive response analogous to the HBO$_2$ treatment of RP cited above. This will be important to understand pharmacologically, since HBO$_2$ may potentially be effective in treatment of different types of chronic pain.

References

1. Bitterman N, Bitterman H: L-arginine-NO pathway and CNS oxygen toxicity. J Appl Physiol 84:1633-1638, 1998

2. Chavko M, Auker CR, McCarron RM: Relationship between protein nitration and oxidation and development of hyperoxic seizures. Nitric Oxide 9:18-23, 2003

3. Chen Y, Nadi NS, Chavko M, Auker CR, McCarron RM: Microarray analysis of gene expression in rat cortical neurons exposed to hyperbaric air and oxygen. Neurochem Res 34:1047-1056, 2009

4. Dall'Era MA, Hampson NB, Hsi RA, Madsen B, Corman JM: Hyperbaric oxygen therapy for radiation induced proctopathy in men treated for prostate cancer. J Urol 176:87-90, 2006

5. Demchenko IT, Boso AE, Whorton AR, Piantadosi CA: Nitric oxide production is enhanced in rat brain before oxygen-induced convulsions. Brain Res 917:253-261, 2001

6. Di Sabato F, Fusco BM, Pelaia P, Giacovazzo M: Hyperbaric oxygen therapy in cluster headache. Pain 52:243-245, 1993

7. Elayan IM, Axley MJ, Prasad PV, Ahlers ST, Auker CR: Effect of hyperbaric oxygen treatment on nitric oxide and oxygen free radicals in rat brain. J Neurophysiol 83:2022-2029, 2000

8. Emmanouil DE, Dickens AS, Heckert RW, Ohgami Y, Chung E, Han S, Quock RM: Nitrous oxide-antinociception is mediated by opioid receptors and nitric oxide in the periaqueductal gray region of the brain. Eur Neuropsychopharmacol 18:194-199, 2008

9. Feldmeier JJ (ed): Hyperbaric Oxygen 2003 – Indications and Results. The UHMS Hyperbaric Oxygen Therapy Committee Report. Durham, NC, Undersea and Hyperbaric Medical Society, 2003

10. Haley TJ, McCormick WG: Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br J Pharmacol 12:12-15, 1957

11. Hirata T, Cui YJ, Funakoshi T, Mizukami Y, Ishikawa Y-I, Shibasaki F, Matsumoto M, Sakabe T: The temporal profile of genomic responses and protein synthesis in ischemic tolerance of the rat brain induced by repeated hyperbaric oxygen. Brain Res 1130:214-222, 2007

12. Jain KK: Physical, physiological, and biochemical aspects of hyperbaric oxygenation, in Jain KK (ed): Textbook of Hyperbaric Medicine, (3rd ed.). Seattle, WA, Hogrefe and Huber Publishers, 1999, pp 11-27

13. Jones K, Evans AW, Bristow RG, Levin W: Treatment of radiation proctitis with hyperbaric oxygen. Radiother Oncol 78:91-94, 2006

14. Kiralp MZ, Yildiz S, Vural D, Keskin I, Ay H, Dursun H: Effectiveness of hyperbaric oxygen therapy in the treatment of complex regional pain syndrome. J Int Med Res 32:258-262, 2004

15. Lee CC, Chen SC, Tsai SC, Wang BW, Liu YC, Lee HM, Shyu KG: Hyperbaric oxygen induces VEGF expression through ERK, JNK and c-Jun/AP-1 activation in human umbilical vein endothelial cells. J Biomed Sci 13:143-156, 2006

16. Liu W, Li J, Sun X, Liu K, Zhang JH, Xu W, Tao H: Repetitive hyperbaric oxygen exposures enhance sensitivity to convulsion by upregulation of eNOS and nNOS. Brain Res 1201:128-134, 2008

17. Myers DE, Myers RA: A preliminary report on hyperbaric oxygen in the relief of migraine headache. Headache 35:197-199, 1995

18. Nakabayashi M, Beard C, Kelly SM, Carr-Locke DL, Oh WK: Treatment of a radiation-induced rectal ulcer with hyperbaric oxygen therapy in a man with prostate cancer. Urol Oncol 24:503-508, 2006

19. Ohgami Y, Chung E, Shirachi DY, Quock RM: Influence of hyperbaric oxygen on regional brain levels and spinal cord levels of nitric oxide metabolites in rat. Brain Res Bull 75:668-673, 2008

20. Ohgami Y, Zylstra CC, Quock LP, Chung E, Shirachi DY, Quock RM: Nitric oxide in hyperbaric oxygen-induced acute antinociception in mice. NeuroReport 20:1325-1329, 2009

21. Peach G: Hyperbaric oxygen and the reflex sympathetic dystrophy syndrome: a case report. Undersea Hyperb Med 22:407-408, 1995

22. Sümen G: Çimşit M, Eroğlu L: Hyperbaric oxygen treatment reduces carrageenan-induced acute inflammation in rats. Eur J Pharmacol 431:265-268, 2001

23. Takeyama N, Sakai H, Ohtake H, Mashitori H, Tamai K, Saotome K: Effects of hyperbaric oxygen on gene expressions of procollagen, matrix metalloproteinase and tissue inhibitor of metalloproteinase in injured medial collateral ligament and anterior cruciate ligament. Knee Surg Sports Traumatol Arthrosc 15:443-452, 2007

24. Thom SR, Bhopale V, Fisher D, Manevich Y, Huang PL, Buerk DG: Stimulation of nitric oxide synthase in cerebral cortex due to elevated partial pressures of oxygen: An oxidative stress response. J Neurobiol 51:85-100, 2002

25. Tuter NV, Danilov AB, Poliakova LV: The treatment of a complex regional pain syndrome. Zh Nevrol Psikhiatr Im S S Korsakova 97:33-35, 1997

26. Vingolo EM, Pelaia P, Forte R, Rocco M, Giusti C, Rispoli E: Does hyperbaric oxygen (HBO) delivery rescue retinal photoreceptors in retinitis pigmentosa? Doc Ophthalmol 97:33-39, 1999

27. Vingolo EM, Rocco M, Grenga P, Salvatore S, Pelaia P: Slowing the degenerative process, long lasting effect of hyperbaric oxygen therapy in retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 246:93-98, 2008

28. Warren J, Sacksteder MR, Thuning CA: Therapeutic effect of prolonged hyperbaric oxygen in adjuvant arthritis of the rat. Arthritis Rheum 22:334-339, 1979

29. Wilson HD, Toepfer VE, Senapati AK, Wilson JR, Fuchs PN: Hyperbaric oxygen treatment is comparable to acetylsalicylic acid treatment in an animal model of arthritis. J Pain 8:924-930, 2007

30. Wilson HD, Wilson JR, Fuchs PN: Hyperbaric oxygen treatment decreases inflammation and mechanical hypersensitivity in an animal model of inflammatory pain. Brain Res 1098:126-128, 2006

31. Wilson JR, Foresman BH, Gamber RG, Wright T: Hyperbaric oxygen in the treatment of migraine with aura. Headache 38:112-115, 1998

32. Yildiz S, Kiralp MZ, Akin A, Keskin I, Ay H, Dursun H, Cimsit M: A new treatment modality for fibromyalgia syndrome: Hyperbaric oxygen therapy. J Int Med Res 32:263-267, 2004

33. Zelinski LM, Ohgami Y, Chung E, Shirachi DY, Quock RM: A prolonged NO-dependent, opioid-mediated antinociceptive effect of hyperbaric oxygen in mice. J Pain 10:167-172, 2009